ALK and non-small cell lung carcinoma: Between June 4, 2014, and September 21, 2015, a total of 222 patients with crizotinib-refractory ALK+ NSCLC were enrolled and allocated to arm A (n = 112) or arm B (n = 110) in ALTA.